DE2236930A1
(de)
|
1971-08-03 |
1973-02-15 |
Cameroun Etat |
Verfahren zur herstellung von desmosterol
|
GB1447456A
(en)
|
1973-06-20 |
1976-08-25 |
Teijin Ltd |
Process for preparing desmosterols
|
JPS54123371A
(en)
|
1978-03-18 |
1979-09-25 |
Yoshio Katsuta |
Mat for electric mosquitoorepellent incense
|
GB8607294D0
(en)
|
1985-04-17 |
1986-04-30 |
Ici America Inc |
Heterocyclic amide derivatives
|
JPS6250441A
(ja)
|
1986-06-06 |
1987-03-05 |
Mitsubishi Metal Corp |
すぐれた耐摩耗性を有する炭化物分散型鉄基焼結合金
|
DE3823318A1
(de)
|
1988-07-09 |
1990-02-22 |
Bayer Ag |
(hetero)aryloxynaphthaline mit ueber schwefel gebundenen substituenten
|
US5229115A
(en)
|
1990-07-26 |
1993-07-20 |
Immunex Corporation |
Adoptive immunotherapy with interleukin-7
|
AU1273992A
(en)
|
1991-01-16 |
1992-08-27 |
Schering Corporation |
Use of interleukin-10 in adoptive immunotherapy of cancer
|
TW263508B
(es)
|
1991-02-12 |
1995-11-21 |
Pfizer |
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
DE19523446A1
(de)
|
1995-06-28 |
1997-01-02 |
Bayer Ag |
Benzotriazole
|
AU6490396A
(en)
|
1995-07-14 |
1997-02-18 |
Smithkline Beecham Corporation |
Substituted-pent-4-ynoic acids
|
NZ315634A
(en)
|
1995-08-10 |
1998-11-25 |
Bayer Ag |
Halobenzimidazoles and their use as microbicides
|
NZ324834A
(en)
|
1995-12-28 |
2001-11-30 |
Fujisawa Pharmaceutical Co |
Benzimidazole derivatives and their use in reducing blood sugar or as inhibitors of PDE5 activity
|
WO1997048697A1
(en)
|
1996-06-19 |
1997-12-24 |
Rhone-Poulenc Rorer Limited |
Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
|
AU724541B2
(en)
|
1996-06-21 |
2000-09-21 |
Allergan, Inc. |
Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
IL129928A0
(en)
|
1996-11-19 |
2000-02-29 |
Amgen Inc |
Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
|
US6392010B1
(en)
|
1996-12-19 |
2002-05-21 |
Aventis Pharmaceuticals Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
|
US6828344B1
(en)
|
1998-02-25 |
2004-12-07 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
JP4327915B2
(ja)
|
1998-03-30 |
2009-09-09 |
株式会社デ・ウエスタン・セラピテクス研究所 |
スルフォンアミド誘導体
|
ATE310001T1
(de)
|
1998-09-18 |
2005-12-15 |
Abbott Gmbh & Co Kg |
4-aminopyrrolopyrimidine als kinaseinhibitoren
|
US6348032B1
(en)
|
1998-11-23 |
2002-02-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with benzimidazole derivatives
|
US6534535B1
(en)
|
1999-08-12 |
2003-03-18 |
Millennium Pharmaceuticals, Inc. |
Inhibitors of factor Xa
|
JP2003506491A
(ja)
|
1999-08-13 |
2003-02-18 |
バイオジェン インコーポレイテッド |
細胞接着インヒビター
|
EP1218336A2
(en)
|
1999-09-20 |
2002-07-03 |
Takeda Chemical Industries, Ltd. |
Melanin concentrating hormone antagonist
|
AU2001285018A1
(en)
|
2000-08-17 |
2002-02-25 |
Agensys, Inc. |
Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
|
CA2427467C
(en)
|
2000-11-09 |
2010-01-12 |
Neopharm, Inc. |
Sn-38 lipid complexes and methods of use
|
TWI239942B
(en)
|
2001-06-11 |
2005-09-21 |
Dainippon Pharmaceutical Co |
N-arylphenylacetamide derivative and pharmaceutical composition containing the same
|
RU2004106540A
(ru)
|
2001-08-03 |
2005-07-27 |
Шеринг Корпорейшн (US) |
Новые ингибиторы гамма-секретазы
|
AU2002327096B2
(en)
|
2001-08-17 |
2007-11-22 |
Sankyo Agro Company, Limited |
3-phenoxy-4-pyridazinol derivative and herbicide composition containing the same
|
WO2003104428A2
(en)
|
2002-01-21 |
2003-12-18 |
Vaccinex, Inc. |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
DE10229777A1
(de)
|
2002-07-03 |
2004-01-29 |
Bayer Ag |
Indolin-Phenylsulfonamid-Derivate
|
FR2845382A1
(fr)
|
2002-10-02 |
2004-04-09 |
Sanofi Synthelabo |
Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
|
US6894061B2
(en)
|
2002-12-04 |
2005-05-17 |
Wyeth |
Substituted dihydrophenanthridinesulfonamides
|
UA80171C2
(en)
|
2002-12-19 |
2007-08-27 |
Pfizer Prod Inc |
Pyrrolopyrimidine derivatives
|
BR0317572A
(pt)
|
2002-12-20 |
2005-11-22 |
Warner Lambert Co |
Benzoxazinas e seus derivados como inibidores de pi3ks
|
JP4601038B2
(ja)
|
2003-03-26 |
2010-12-22 |
第一三共株式会社 |
インドリルマレイミド類
|
US20080199486A1
(en)
|
2003-05-12 |
2008-08-21 |
Yair Argon |
Grp94-based compositions and methods of use thereof
|
US7138401B2
(en)
|
2003-09-18 |
2006-11-21 |
Conforma Therapeutics Corporation |
2-aminopurine analogs having HSP90-inhibiting activity
|
AU2004275444A1
(en)
|
2003-09-26 |
2005-04-07 |
Forbes Medi-Tech Inc. |
Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
|
WO2005033048A2
(en)
|
2003-09-29 |
2005-04-14 |
The Johns Hopkins University |
Wnt pathway antagonists
|
US8067608B2
(en)
|
2003-09-29 |
2011-11-29 |
The Johns Hopkins University |
Hedgehog pathway antagonists
|
SE0302760D0
(sv)
|
2003-10-20 |
2003-10-20 |
Biovitrum Ab |
New compounds
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
WO2005058847A1
(en)
*
|
2003-12-09 |
2005-06-30 |
F. Hoffmann-La Roche Ag |
Benzoxazine derivatives and uses thereof
|
WO2005063766A2
(en)
|
2003-12-23 |
2005-07-14 |
Novartis Ag |
Bicyclic heterocyclic p-38 kinase inhibitors
|
WO2005084208A2
(en)
|
2004-02-27 |
2005-09-15 |
New York University |
A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
|
WO2005120558A2
(en)
|
2004-05-25 |
2005-12-22 |
University Of Connecticut Health Center |
Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
EP1771204A4
(en)
|
2004-07-01 |
2008-08-13 |
Univ New York |
COMPOSITIONS AND METHODS FOR MODULATING ROR GAMMA T
|
FR2874011B1
(fr)
|
2004-08-03 |
2007-06-15 |
Sanofi Synthelabo |
Derives de sulfonamides, leur preparation et leur application en therapeutique
|
US20070010537A1
(en)
|
2004-08-20 |
2007-01-11 |
Kazumasa Hamamura |
Fused pyramidine derivative and use thereof
|
US7304073B2
(en)
|
2004-08-20 |
2007-12-04 |
Wyeth |
Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors
|
US7652043B2
(en)
|
2004-09-29 |
2010-01-26 |
The Johns Hopkins University |
WNT pathway antagonists
|
DK1809321T3
(da)
|
2004-10-08 |
2012-06-25 |
Us Gov Health & Human Serv |
Adoptiv immunterapi med forøget T-lymfocytoverlevelse
|
US20060269973A1
(en)
|
2004-11-24 |
2006-11-30 |
Cassian Yee |
Methods of using IL-21 for adoptive immunotherapy and identification of tumor antigens
|
AR051780A1
(es)
|
2004-11-29 |
2007-02-07 |
Japan Tobacco Inc |
Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
|
GB0514911D0
(en)
|
2005-07-20 |
2005-08-24 |
Univ Birmingham |
T cell memory assay
|
US8003624B2
(en)
|
2005-08-25 |
2011-08-23 |
Schering Corporation |
Functionally selective ALPHA2C adrenoreceptor agonists
|
EP1945626B1
(en)
|
2005-08-25 |
2011-07-27 |
Schering Corporation |
Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
|
CA2620894A1
(en)
|
2005-09-01 |
2007-03-08 |
Janssen Pharmaceutica N.V. |
Novel benzopyran derivatives as potassium channel openers
|
WO2007031429A1
(en)
|
2005-09-15 |
2007-03-22 |
F. Hoffmann-La Roche Ag |
Novel heterobicyclic derivatives useful as inhibitors of liver carnitine palmitoyl transferase
|
FR2896798A1
(fr)
|
2006-01-27 |
2007-08-03 |
Sanofi Aventis Sa |
Derives de sulfonamides, leur preparation et leur application en therapeutique
|
AU2007214594B2
(en)
|
2006-02-13 |
2010-11-11 |
F. Hoffmann-La Roche Ag |
Heterobicyclic sulfonamide derivatives for the treatment of diabetes
|
PL1984357T3
(pl)
|
2006-02-17 |
2014-03-31 |
Rigel Pharmaceuticals Inc |
Związki 2,4-pirymidynodiaminy do leczenia lub zapobiegania chorób autoimmunologicznych
|
MX2008011302A
(es)
|
2006-03-01 |
2008-11-04 |
Janssen Pharmaceutica Nv |
Tratamiento de cancer que combina agente de linfodeplecion con linfocitos t citotoxicos y citocinas.
|
US20100280268A1
(en)
|
2006-04-06 |
2010-11-04 |
Dams Gery Karel Julia |
Homogeneous time resolved fluorescence based test system
|
US7998978B2
(en)
|
2006-05-01 |
2011-08-16 |
Pfizer Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
US20080305169A1
(en)
|
2006-05-26 |
2008-12-11 |
Japan Tobacco Inc. |
Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
|
JP2009538910A
(ja)
|
2006-06-01 |
2009-11-12 |
ワイス |
5−ヒドロキシトリプタミン−6リガンドとしての1−スルホニルインダゾリルアミン誘導体および1−スルホニルインダゾリルアミド誘導体
|
AU2007271188B2
(en)
|
2006-07-03 |
2012-11-01 |
Proximagen Limited |
Indoles as 5-HT6 modulators
|
AU2007272452A1
(en)
|
2006-07-12 |
2008-01-17 |
Oncotx, Inc. |
Compositions and methods for targeting cancer-specific transcription complexes
|
TWI315304B
(en)
|
2006-08-31 |
2009-10-01 |
Univ Taipei Medical |
Indoline-sulfonamides compounds
|
US8389739B1
(en)
|
2006-10-05 |
2013-03-05 |
Orphagen Pharmaceuticals |
Modulators of retinoid-related orphan receptor gamma
|
US20090275586A1
(en)
|
2006-10-06 |
2009-11-05 |
Kalypsys, Inc. |
Heterocyclic inhibitors of pde4
|
WO2008062740A1
(fr)
|
2006-11-20 |
2008-05-29 |
Japan Tobacco Inc. |
Composé azoté à anneaux fusionnés et son utilisation
|
US7799933B2
(en)
|
2006-12-21 |
2010-09-21 |
Hoffman-La Roche Inc. |
Sulfonamide derivatives
|
US20080186971A1
(en)
|
2007-02-02 |
2008-08-07 |
Tarari, Inc. |
Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
|
US20100179143A1
(en)
|
2007-05-29 |
2010-07-15 |
Smithkline Beecham Corporation |
Naphthyridine, derivatives as p13 kinase inhibitors
|
ES2424976T3
(es)
|
2007-06-03 |
2013-10-10 |
Oncotx, Inc. |
Isoformas relativas al cáncer de componentes de complejos de factores de transcripción como biomarcadores y dianas de fármacos
|
US7776877B2
(en)
|
2007-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
|
EP2197876A1
(en)
|
2007-08-29 |
2010-06-23 |
Glaxosmithkline LLC |
Thiazole and oxazole kinase inhibitors
|
WO2009035997A2
(en)
|
2007-09-14 |
2009-03-19 |
Cara Therapeutics, Inc. |
Benzo-fused heterocycles
|
US8541185B2
(en)
|
2007-09-24 |
2013-09-24 |
Technion Research & Development Foundation Limited |
Method of predicting responsiveness to autologous adoptive cell transfer therapy
|
US20090131523A1
(en)
|
2007-10-15 |
2009-05-21 |
Enzymotec Ltd. |
Lipid compositions for the treatment and prevention of proliferative diseases and for the reduction of incidences of mutagenesis and carinogenesis
|
RU2364597C1
(ru)
|
2007-12-14 |
2009-08-20 |
Андрей Александрович Иващенко |
ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
|
US7960377B2
(en)
|
2008-03-28 |
2011-06-14 |
Cara Therapeutics, Inc. |
Substituted pyridoxazines
|
ES2566339T3
(es)
|
2008-06-05 |
2016-04-12 |
Glaxo Group Limited |
Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
|
WO2009147188A1
(en)
|
2008-06-05 |
2009-12-10 |
Glaxo Group Limited |
Benzpyrazol derivatives as inhibitors of pi3 kinases
|
WO2009147190A1
(en)
|
2008-06-05 |
2009-12-10 |
Glaxo Group Limited |
Novel compounds
|
CA2727373A1
(en)
*
|
2008-06-09 |
2009-12-17 |
Sanofi-Aventis |
Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
|
WO2009149819A1
(en)
|
2008-06-09 |
2009-12-17 |
Sanofi-Aventis |
Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
|
JPWO2009157196A1
(ja)
|
2008-06-25 |
2011-12-08 |
武田薬品工業株式会社 |
アミド化合物
|
AU2009270255B2
(en)
|
2008-07-09 |
2013-12-12 |
Nissan Chemical Corporation |
Process for production of isoxazoline-substituted benzoic acid amide compound
|
WO2010017827A1
(en)
|
2008-08-14 |
2010-02-18 |
European Molecular Biology Laboratory |
6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
|
EP2321407A4
(en)
|
2008-09-11 |
2012-07-18 |
Univ Florida |
SYSTEM AND METHOD FOR THE PRODUCTION OF T-LYMPHOCYTES
|
NZ592008A
(en)
|
2008-10-02 |
2011-12-22 |
Taisho Pharmaceutical Co Ltd |
7-piperidinoalkyl-3,4-dihydroquinolone derivative
|
EP2181710A1
(en)
|
2008-10-28 |
2010-05-05 |
Phenex Pharmaceuticals AG |
Ligands for modulation of orphan receptor-gamma (NR1F3) activity
|
WO2010057101A2
(en)
|
2008-11-17 |
2010-05-20 |
Schering Corporation |
Compounds useful as hiv blockers
|
US8716312B2
(en)
|
2008-11-19 |
2014-05-06 |
Merck Sharp & Dohme Corporation |
Inhibitors of diacylglycerol acyltransferase
|
CN102272153B
(zh)
|
2008-11-24 |
2015-04-15 |
德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 |
高亲和力t细胞受体及其应用
|
UA104447C2
(uk)
|
2008-12-19 |
2014-02-10 |
Сіртріз Фармасьютікалз, Інк. |
Тіазолопіридинові сполуки, що модулюють сиртуїн
|
TW201030007A
(en)
|
2009-02-06 |
2010-08-16 |
Gruenenthal Gmbh |
Substituted spiro-amides as b1r modulators
|
WO2010102958A1
(en)
|
2009-03-09 |
2010-09-16 |
Glaxo Group Limited |
4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
|
TW201102391A
(en)
|
2009-03-31 |
2011-01-16 |
Biogen Idec Inc |
Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
|
WO2010123139A1
(ja)
|
2009-04-24 |
2010-10-28 |
持田製薬株式会社 |
スルファモイル基を有するアリールカルボキサミド誘導体
|
MA33304B1
(fr)
|
2009-04-30 |
2012-05-02 |
Glaxo Group Ltd |
Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase
|
US9499627B2
(en)
|
2009-08-03 |
2016-11-22 |
University Of Miami |
Method for in vivo expansion of T regulatory cells
|
WO2011019634A2
(en)
|
2009-08-10 |
2011-02-17 |
Taipei Medical University |
Aryl substituted sulfonamide compounds and their use as anticancer agents
|
US8383099B2
(en)
|
2009-08-28 |
2013-02-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adoptive cell therapy with young T cells
|
AR078770A1
(es)
|
2009-10-27 |
2011-11-30 |
Elara Pharmaceuticals Gmbh |
Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
|
EP2493888B1
(en)
|
2009-10-29 |
2016-04-06 |
GlaxoSmithKline LLC |
Bicyclic pyridines and analogs as sirtuin modulators
|
EP2507223A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Benzpyrazole derivatives as inhibitors of p13 kinases
|
WO2011067366A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Indazole derivatives as pi 3 - kinase inhibitors
|
US20120238559A1
(en)
|
2009-12-03 |
2012-09-20 |
Glaxo Group Limited |
Novel compounds
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
US20110142814A1
(en)
|
2009-12-16 |
2011-06-16 |
New York University |
Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy
|
CA2791738C
(en)
|
2010-03-01 |
2020-06-09 |
Gtx, Inc. |
Aryl imidazolyl compounds for the treatment of cancer
|
IL300733A
(en)
|
2010-03-05 |
2023-04-01 |
Univ Johns Hopkins |
Compositions and methods for antibodies and fusion proteins targeting immune modulation
|
WO2011115892A1
(en)
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
GB201013443D0
(en)
|
2010-08-11 |
2010-09-22 |
Cytovac As |
Compositions and methods for producing dendritic cells
|
PL2614058T3
(pl)
|
2010-09-08 |
2015-12-31 |
Glaxosmithkline Ip Dev Ltd |
Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
|
JP5876051B2
(ja)
|
2010-09-08 |
2016-03-02 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
|
JP5906244B2
(ja)
|
2010-09-13 |
2016-04-20 |
マイクロバイオティックス・インコーポレーテッド |
哺乳類細胞中へのウイルスの侵入の阻害剤
|
WO2012037108A1
(en)
|
2010-09-13 |
2012-03-22 |
Glaxosmithkline Llc |
Aminoquinoline derivatives as antiviral agents
|
US9512111B2
(en)
|
2010-11-08 |
2016-12-06 |
Lycera Corporation |
N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
|
CN108103085A
(zh)
|
2010-12-09 |
2018-06-01 |
宾夕法尼亚大学董事会 |
嵌合抗原受体-修饰的t细胞治疗癌症的用途
|
EP2487159A1
(en)
|
2011-02-11 |
2012-08-15 |
MSD Oss B.V. |
RorgammaT inhibitors
|
EP3184117B1
(en)
|
2011-03-22 |
2020-01-08 |
The Brigham And Women's Hospital, Inc. |
Compositions and their use in the treatment of cancer
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
SG10201602253SA
(en)
|
2011-03-23 |
2016-05-30 |
Hutchinson Fred Cancer Res |
Method and compositions for cellular immunotherapy
|
WO2012130306A1
(en)
|
2011-03-30 |
2012-10-04 |
Elara Pharmaceuticals Gmbh |
Bicyclic 2,3-dihyrdobenzazine compounds for use in therapy
|
EP2511263A1
(en)
|
2011-04-14 |
2012-10-17 |
Phenex Pharmaceuticals AG |
Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
|
WO2012158784A2
(en)
|
2011-05-16 |
2012-11-22 |
Theodore Mark Kamenecka |
Modulators of the nuclear hormone receptor ror
|
KR102164567B1
(ko)
|
2011-06-24 |
2020-10-12 |
쥐알아이 바이오,아이엔씨. |
염증 질환의 예방 및 치료
|
BR112014003704A2
(pt)
|
2011-09-19 |
2017-03-07 |
Eth Zuerich |
moduladores ror gama
|
GB201116641D0
(en)
|
2011-09-27 |
2011-11-09 |
Glaxo Group Ltd |
Novel compounds
|
US10391126B2
(en)
|
2011-11-18 |
2019-08-27 |
Board Of Regents, The University Of Texas System |
CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
|
NZ629283A
(en)
|
2012-03-16 |
2016-04-29 |
Covagen Ag |
Novel binding molecules with antitumoral activity
|
AU2013259624B2
(en)
|
2012-05-08 |
2017-10-19 |
Lycera Corporation |
Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
|
US9657033B2
(en)
|
2012-05-08 |
2017-05-23 |
Lycera Corporation |
Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
|
WO2013167136A1
(en)
|
2012-05-08 |
2013-11-14 |
Herlev Hospital |
Improving adoptive cell therapy with interferon gamma
|
BR112014028023A2
(pt)
|
2012-05-08 |
2017-06-27 |
Lycera Corp |
composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade de il-17 em um indivíduo e método para inibir a atividade de rory
|
EP2856142A1
(en)
|
2012-05-25 |
2015-04-08 |
Health Diagnostic Laboratory, Inc. |
Rapid and high-throughput analysis of sterols/stanols or derivatives thereof
|
WO2014026329A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
|
WO2014026330A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
WO2014026328A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
|
WO2014028669A1
(en)
|
2012-08-15 |
2014-02-20 |
Biogen Idec Ma Inc. |
Novel compounds for modulation of ror-gamma activity
|
WO2014026327A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
|
MX362456B
(es)
|
2012-08-24 |
2019-01-18 |
Univ California |
Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
|
EP2931267A1
(en)
|
2012-12-17 |
2015-10-21 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
|
US20150017120A1
(en)
|
2013-06-13 |
2015-01-15 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
|
EP3044219A1
(en)
*
|
2013-09-09 |
2016-07-20 |
Bristol-Myers Squibb Company |
Rorgamma modulators
|
US9783511B2
(en)
|
2013-12-20 |
2017-10-10 |
Lycera Corporation |
Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
|
US9663502B2
(en)
|
2013-12-20 |
2017-05-30 |
Lycera Corporation |
2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
|
WO2015095795A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
|
CA2939305A1
(en)
|
2014-02-27 |
2015-09-03 |
Lycera Corporation |
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
|
US10189777B2
(en)
|
2014-05-05 |
2019-01-29 |
Lycera Corporation |
Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
|
CA2947290A1
(en)
*
|
2014-05-05 |
2015-11-12 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
WO2016179343A1
(en)
|
2015-05-05 |
2016-11-10 |
Lycera Corporation |
DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
|
US10611740B2
(en)
|
2015-06-11 |
2020-04-07 |
Lycera Corporation |
Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
WO2018165501A1
(en)
|
2017-03-10 |
2018-09-13 |
Lycera Corporation |
INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATMENT OF DISEASE
|